Ipamorelin: The Selective Growth Hormone Secretagogue Explained
Ipamorelin is the cleanest GHRP available for research — selective GH release without the cortisol, prolactin, or appetite side effects of older compounds. Here's a complete research guide.
Ipamorelin is a pentapeptide growth hormone releasing peptide (GHRP) developed in the late 1990s. It belongs to the same class as GHRP-2 and GHRP-6 but was specifically engineered to address their limitations — primarily their non-selective stimulation of cortisol and prolactin alongside growth hormone. The result is the most selective GHRP available for research.
How Ipamorelin Works
Ipamorelin is a ghrelin mimetic — it binds to the growth hormone secretagogue receptor 1a (GHS-R1a) in the anterior pituitary gland. This binding triggers a pulse of growth hormone (GH) release from somatotroph cells.
The GH pulse then drives downstream effects through the GH/IGF-1 axis:
- ·The liver converts GH signals into IGF-1 (insulin-like growth factor 1)
- ·IGF-1 mediates most of GH's anabolic and metabolic effects in peripheral tissue
- ·The pulse pattern matters: GH works through discrete pulses, not continuous elevation — Ipamorelin mimics this natural pattern
What Makes Ipamorelin Different
The comparison to first-generation GHRPs is important for understanding why Ipamorelin has become the most studied compound in its class:
| Compound | GH Release | Cortisol | Prolactin | Appetite |
|---|---|---|---|---|
| GHRP-6 | Strong | Significant increase | Increase | Strong stimulation |
| GHRP-2 | Strong | Moderate increase | Increase | Moderate stimulation |
| Ipamorelin | Strong | Minimal/no increase | Minimal/no increase | Minimal stimulation |
This selectivity profile makes Ipamorelin the preferred GHRP for research that requires isolated GH pathway stimulation without confounding variables from cortisol or appetite changes.
Research Applications
Muscle and Body Composition
GH and its downstream IGF-1 signal are well-established drivers of muscle protein synthesis and lipolysis. Ipamorelin research has examined:
- ·Lean mass preservation in caloric deficit models
- ·Muscle fiber hypertrophy in combination with resistance protocols
- ·Body fat reduction, particularly in visceral adipose tissue
- ·Recovery from muscle injury (complementary to healing peptides like BPC-157)
Bone Density
IGF-1 is a potent anabolic signal for bone. Research has documented Ipamorelin's effects on bone mineral density in aged animal models, with improvements in trabecular bone architecture and resistance to fracture.
Sleep and Recovery
GH secretion is highest during slow-wave (deep) sleep, and the relationship is bidirectional — GH supports sleep architecture, and sleep deprivation reduces GH output. Research protocols studying Ipamorelin's effects on sleep quality and recovery markers typically time administration near sleep onset to align with the natural GH secretion window.
Age-Related GH Decline
GH output declines approximately 15% per decade after age 30. By age 60, GH pulse amplitude is typically less than 25% of peak young-adult levels. Ipamorelin research has explored whether exogenous GHRP stimulation can restore more youthful GH pulsatility in aged subjects — animal studies show significant restoration of GH pulse amplitude with maintained selectivity.
Stacking with CJC-1295
Ipamorelin is most commonly studied in combination with CJC-1295 (without DAC), a GHRH analogue. The two compounds target different but synergistic receptors:
- ·CJC-1295 acts at GHRH receptors, priming the pituitary for release
- ·Ipamorelin acts at GHS-R1a, providing the direct trigger
When administered simultaneously, the two compounds produce a GH pulse significantly greater than either compound alone. This synergy is the basis for their widespread use as a research combination. See the Ipamorelin and CJC-1295 guide for a full comparison of the two compounds and detailed protocol considerations.
Reconstitution and Storage
Ipamorelin is supplied as a lyophilized powder. Reconstitute with bacteriostatic water by gently injecting the liquid down the vial wall — do not squirt directly onto the powder. Swirl gently to dissolve. Store reconstituted solution at 2–8°C and use within 30 days. Lyophilized powder stores at -20°C for long-term stability.
Use the peptide dosing calculator to calculate exact syringe volumes for your research protocol, and see the peptide reconstitution guide for step-by-step preparation.
Browse the full peptide catalogue or read the tesamorelin guide for a comparison with another GH-axis peptide that operates upstream via GHRH agonism.
Note: Ipamorelin is sold strictly for research purposes. Not for human use.